Neurolixis, Inc. Press releases
Mar 12, 2019
The US Food and Drug Administration (FDA) gave a positive response to Neurolixis' Investigational New Drug (IND) application for NLX-112.
Feb 20, 2019
Neurolixis launched a collaboration with the GALA® laboratory in Castres, France. GALA® is a platform of the Rapsodee/IMT Mines Albi research facility specialized in developing novel drug formulations.
Feb 11, 2019
A new article in the Journal of Medicinal Chemistry describes the characterization of novel selective serotonin 5-HT1A receptor biased agonists.
Feb 22, 2016
Neurolixis, Inc. announced the recent publication of two scientific articles demonstrating robust effects of the Company’s lead drug candidate, NLX-112, in rodent models of Parkinson’s disease.
Nov 22, 2015
Neurolixis Inc., a privately held biotechnology company developing therapies for disorders of the central nervous system (CNS), today announced that it had appointed Steven A.
Jun 24, 2015
Neurolixis Inc. announced that it had been awarded a second research grant by the Rett Syndrome Research Trust (RSRT) to support the development of its novel serotonin 5-HT1A receptor agonist, NLX-101.
Jun 09, 2015
Neurolixis, Inc., a private biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, will present the latest preclinical data on its drug candidate, NLX-112, at the 19th International Congress of...
Jun 04, 2015
Neurolixis SAS, the French subsidiary of Neurolixis Inc., a privately held biotechnology company, announced today that it had been awarded 'Jeune Entreprise Innovante' (JEI; literally 'Young Innovative Company') status by the French Public Finances...
May 29, 2015
Neurolixis Inc., a privately held biotechnology company developing therapies for disorders of the central nervous system (CNS), today announced that it had appointed Mark Corrigan, M.D. to its Advisory Board. Dr.
Apr 21, 2015
Dana Point, CA, April 21, 2015 -- Neurolixis, Inc., a biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, today announced that Dr. Mark A.